Jupiter Neurosciences begins patient enrollment for Parkinson's trial

May 27, 2026 7:30 AM

Jupiter Neurosciences Inc. (NASDAQ: JUNS) has started patient enrollment for its Phase 2a RESET clinical trial evaluating JOTROL, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found